Jin Jing, Peng Dao-Quan, Gong Hao, Zhao Shui-Ping, Ning Xiao-Hui, Li Song-Lin, Wang Shu-Hui
Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha Hunan 410011, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Aug;38(8):706-10.
To observe the relationship between serum and monocyte-derived-macrophages secreted adipocyte fatty acid binding protein (A-FABP), adiponectin (or A-FABP/adiponectin ratio) and coronary artery disease.
Three hundred and forty subjects underwent coronary angiography (CAG) were classified into CAD group (n = 211) and non-CAD group (n = 129) according to the CAG results. The severity of coronary artery stenosis was assessed by the numbers of involved coronary artery branches and the sum of the Gensini scores. Fasting venous blood was collected from all subjects and peripheral monocytes were isolated from 20 subjects (10 selected from each group with age-, gender-, and BMI-matched). Peripheral blood monocytes were obtained and stimulated into macrophages with PMA, cell culture supernatant was collected. The concentration of serum/supernatant A-FABP and adiponectin levels were assayed by enzyme-linked immunosorbent assays.
(1) A-FABP levels tended to be higher in CAD patients compared to non-CAD subjects [18.3(13.2, 22.8) µg/L vs. 16.4(13.5, 20.4) µg/L, P = 0.088]. The concentration of adiponectin in CAD group was significantly lower than those in non-CAD group [13.9 (9.8, 17.1) mg/L vs. 19.7 (14.5, 27.6) mg/L, P < 0.05]. (2) The A-FABP levels increased and the adiponectin levels decreased as the number of stenotic vessels increased. Gensini scores were positively correlated with serum A-FABP (r = 0.120, P = 0.043) and inversely correlated with adiponectin (r = -0.405, P = 0.007). (3) The difference in A-FABP/adiponectin ratio was more prominent between subjects with CAD and subjects without CAD [(1.51 ± 0.79) µg/mg vs. (0.89 ± 0.30) µg/mg, P < 0.01] and there was a stronger positive correlation of Gensini score to A-FABP/adiponectin ratio(r = 0.531, P = 0.000). (4) Monocyte-derived-macrophages from patients with CAD had higher A-FABP/adiponectin ratio than that in patients without CAD [(0.51 ± 0.19) µg/mg vs. (0.36 ± 0.11) µg/mg, P < 0.05].
Increased levels of serum A-FABP and reduced levels of adiponectin in CAD patients serves as a novel biomarker for the severity of the coronary stenosis. A-FABP/adiponectin ratio is superior to A-FABP or adiponectin alone on predicting CAD risks.
观察血清及单核细胞来源巨噬细胞分泌的脂肪细胞脂肪酸结合蛋白(A-FABP)、脂联素(或A-FABP/脂联素比值)与冠状动脉疾病之间的关系。
对340例行冠状动脉造影(CAG)的受试者,根据CAG结果分为冠心病组(n = 211)和非冠心病组(n = 129)。通过受累冠状动脉分支数量和Gensini评分总和评估冠状动脉狭窄的严重程度。采集所有受试者的空腹静脉血,并从20名受试者(每组各选10名,年龄、性别和BMI匹配)中分离出外周血单核细胞。获取外周血单核细胞并用佛波酯刺激使其分化为巨噬细胞,收集细胞培养上清液。采用酶联免疫吸附测定法检测血清/上清液中A-FABP的浓度和脂联素水平。
(1)冠心病患者的A-FABP水平相较于非冠心病受试者有升高趋势[18.3(13.2,22.8)μg/L对16.4(13.5,20.4)μg/L,P = 0.088]。冠心病组脂联素浓度显著低于非冠心病组[13.9(9.8,17.1)mg/L对19.7(14.5,27.6)mg/L,P < 0.05]。(2)随着狭窄血管数量增加,A-FABP水平升高,脂联素水平降低。Gensini评分与血清A-FABP呈正相关(r = 0.120,P = 0.043),与脂联素呈负相关(r = -0.405,P = 0.007)。(3)冠心病患者与非冠心病患者之间A-FABP/脂联素比值的差异更为显著[(1.51±0.79)μg/mg对(0.89±0.30)μg/mg,P < 0.01],且Gensini评分与A-FABP/脂联素比值的正相关性更强(r = 0.531,P = 0.000)。(4)冠心病患者单核细胞来源的巨噬细胞的A-FABP/脂联素比值高于非冠心病患者[(0.51±0.19)μg/mg对(0.36±0.11)μg/mg,P < 0.05]。
冠心病患者血清A-FABP水平升高和脂联素水平降低可作为冠状动脉狭窄严重程度的新型生物标志物。A-FABP/脂联素比值在预测冠心病风险方面优于单独的A-FABP或脂联素。